drugset / Trial / NCT06078670
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy of CVL218 in combination with Toripalimab injection/Sintilimab injection (Darbersol, Sintilimab) in the treatment of advanced solid tumors. It focuses on assessing the safety, tolerability, and pharmacokinetic profile of a three-drug combination regimen comprising albumin-bound paclitaxel injection (Kealil), paclitaxel injection (Taxol), and Fuquinitinib capsule (Aiutec, Fruquintinib).
Timeline
- Start
- 2023-10-10
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVL218 | Unknown | 500 mg | Oral |
| Subject | CVL218 | Unknown | 700 mg | Oral |
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |